CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC (CELZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.11+4.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CELZ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -75.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CELZ — private placement
Dated 2026-07-02
Entry into a Material Definitive Agreement. On June 30, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with the holders (the “Holders”) of warrants to purchase an aggregate of 2,790,340 shares of the Company’s common stock originally issued on October 29, 2025 (collectively, the “Existing Warrants”), pursuant to which the Holders agreed to exercise the Existing Warrants at an exercise price of…
Why it matters: This could signal dilution of existing shares, impacting stock value. Investors will want to see how much dilution occurs.
Worry ifThe disclosure shows fewer shares sold than expected. This means less dilution.
Less concerning ifThe disclosure shows many shares sold. This means high dilution.
Why it matters: Unregistered sales may mean financial issues. They can also reduce the value of shares.
Worry ifMore unregistered sales of stock happen more often.
Less concerning ifNo new unregistered sales were reported in the next quarter.
Why it matters: If healthcare sector revenue growth speeds up, it may help Creative Medical's performance. This could improve investor sentiment.
Supportive ifHealthcare sector revenue growth is speeding up to 9% or more.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: Improving cash flow would show progress in managing losses. This is key for financial stability.
Supportive ifCash flow from operations turns positive in Q3 2026.
Worry ifCash flow from operations remains negative in Q3 2026.
Why it matters: Changes in operating losses show how well the company controls costs. This affects investor trust.
Worry ifOperating losses decrease by more than 10% in Q3 2026.
Less concerning ifOperating losses increase or stay the same in Q3 2026.
Why it matters: New equity transactions can help with money management and financial health. This is important now.
Supportive ifLook for news about new equity transactions or financing in Q3 2026.
Worry ifNo new equity transactions or financing news in Q3 2026.
Why it matters: Warrant exercises can give needed cash. This may help the company's finances.
Supportive ifMore than 1 million shares were exercised from warrants.
Worry ifWarrants are not exercised as the deadline gets closer.
Why it matters: Negative cash flow shows money problems. Investors want to see better results.
Worry ifQ2 cash flow from operations remains negative, worse than -$1.47M.
Less concerning ifCash flow from operations turns positive for Q2.
Why it matters: The private placement could provide needed capital. Success in this area is vital for future operations.
Supportive ifFunds from the private placement are successfully used to improve cash flow or reduce losses.
Worry ifFunds from the private placement do not improve financial metrics.
Why it matters: The earnings report will show how well the company is doing. It will cover both finances and operations.
Watch forEarnings report shows smaller operating losses than in past quarters.
Also watch forThe earnings report shows larger operating losses. It may also show no progress.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$287 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,025 loss on $10,000 · 10.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,830 loss on $10,000 · 88.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.